Does the media prefer CMPS or STRO?

In the previous week, Compass Pathways had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 4 mentions for Compass Pathways and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Compass Pathways' score of 0.72 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STOK or STRO?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Stoke Therapeutics and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Stoke Therapeutics' score of 0.93 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STRO or AMLX?

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Amylyx Pharmaceuticals' score of 0.92 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, STRO or NUVB?

Sutro Biopharma has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sutro Biopharma $102.48M 4.92 -$191.09M -$11.04 N/A Nuvation Bio $62.90M 31.47 -$204.63M -$0.43 N/A

Does the media favor STRO or NUVB?

In the previous week, Nuvation Bio had 6 more articles in the media than Sutro Biopharma. MarketBeat recorded 7 mentions for Nuvation Bio and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Nuvation Bio's score of 0.59 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ATAI or STRO?

Sutro Biopharma has higher revenue and earnings than Atai Beckley. Sutro Biopharma is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 467.19 -$660.05M -$2.23 N/A Sutro Biopharma $102.48M 4.92 -$191.09M -$11.04 N/A

Does the media prefer ATAI or STRO?

In the previous week, Atai Beckley had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Atai Beckley and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Atai Beckley's score of 0.66 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sutro Biopharma (STRO) Competitors

$30.43 +0.19 (+0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$31.16 +0.73 (+2.42%)

As of 06:27 PM Eastern

Compare

STRO vs. CMPS, STOK, AMLX, NUVB, and ATAI

Should you buy Sutro Biopharma stock or one of its competitors? MarketBeat compares Sutro Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sutro Biopharma include Compass Pathways (CMPS), Stoke Therapeutics (STOK), Amylyx Pharmaceuticals (AMLX), Nuvation Bio (NUVB), and Atai Beckley (ATAI). These companies are all part of the "pharmaceutical products" industry.

How does Sutro Biopharma compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Compass Pathways presently has a consensus target price of $23.10, indicating a potential upside of 69.60%. Sutro Biopharma has a consensus target price of $52.44, indicating a potential upside of 72.34%. Given Sutro Biopharma's higher probable upside, analysts plainly believe Sutro Biopharma is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Compass Pathways has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Sutro Biopharma has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Sutro Biopharma	$102.48M	4.92	-$191.09M	-$11.04	N/A

In the previous week, Compass Pathways had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 4 mentions for Compass Pathways and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Compass Pathways' score of 0.72 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Sutro Biopharma	-154.21%	N/A	-69.20%

Summary

Sutro Biopharma beats Compass Pathways on 8 of the 15 factors compared between the two stocks.

How does Sutro Biopharma compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Sutro Biopharma (NASDAQ:STRO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

97.0% of Sutro Biopharma shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Stoke Therapeutics currently has a consensus target price of $41.83, indicating a potential upside of 27.93%. Sutro Biopharma has a consensus target price of $52.44, indicating a potential upside of 72.34%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Stoke Therapeutics had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Stoke Therapeutics and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Stoke Therapeutics' score of 0.93 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Sutro Biopharma has a net margin of -154.21% compared to Stoke Therapeutics' net margin of -529.20%. Sutro Biopharma's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Sutro Biopharma	-154.21%	N/A	-69.20%

Stoke Therapeutics has higher revenue and earnings than Sutro Biopharma. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	11.04	-$6.89M	-$2.81	N/A
Sutro Biopharma	$102.48M	4.92	-$191.09M	-$11.04	N/A

Summary

Sutro Biopharma beats Stoke Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Sutro Biopharma compare to Amylyx Pharmaceuticals?

Sutro Biopharma (NASDAQ:STRO) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sutro Biopharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.2, suggesting that its stock price is 120% less volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Amylyx Pharmaceuticals' score of 0.92 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sutro Biopharma presently has a consensus price target of $52.44, suggesting a potential upside of 72.34%. Amylyx Pharmaceuticals has a consensus price target of $24.25, suggesting a potential upside of 32.73%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Sutro Biopharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Sutro Biopharma. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.92	-$191.09M	-$11.04	N/A
Amylyx Pharmaceuticals	$87.37M	23.25	-$144.74M	-$1.50	N/A

Summary

Sutro Biopharma beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Nuvation Bio?

Sutro Biopharma (NASDAQ:STRO) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Nuvation Bio had 6 more articles in the media than Sutro Biopharma. MarketBeat recorded 7 mentions for Nuvation Bio and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Nuvation Bio's score of 0.59 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sutro Biopharma has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.92	-$191.09M	-$11.04	N/A
Nuvation Bio	$62.90M	31.47	-$204.63M	-$0.43	N/A

Sutro Biopharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sutro Biopharma presently has a consensus price target of $52.44, indicating a potential upside of 72.34%. Nuvation Bio has a consensus price target of $12.50, indicating a potential upside of 119.88%. Given Nuvation Bio's higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Nuvation Bio has a net margin of -102.06% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Summary

Sutro Biopharma and Nuvation Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Sutro Biopharma has higher revenue and earnings than Atai Beckley. Sutro Biopharma is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	467.19	-$660.05M	-$2.23	N/A
Sutro Biopharma	$102.48M	4.92	-$191.09M	-$11.04	N/A

In the previous week, Atai Beckley had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Atai Beckley and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Atai Beckley's score of 0.66 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 26.8% of Atai Beckley shares are held by insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Atai Beckley has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Atai Beckley currently has a consensus price target of $16.00, suggesting a potential upside of 208.29%. Sutro Biopharma has a consensus price target of $52.44, suggesting a potential upside of 72.34%. Given Atai Beckley's higher possible upside, research analysts clearly believe Atai Beckley is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Sutro Biopharma has a net margin of -154.21% compared to Atai Beckley's net margin of -19,019.44%. Sutro Biopharma's return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Sutro Biopharma	-154.21%	N/A	-69.20%

Summary

Atai Beckley and Sutro Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STRO vs. The Competition

Export

Metric	Sutro Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$501.09M	$3.65B	$6.82B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	6.64%
P/E Ratio	-2.76	21.43	27.94	24.55
Price / Sales	4.92	322.66	533.88	98.03
Price / Cash	N/A	143.20	48.59	58.15
Price / Book	-1.97	8.66	10.91	6.45
Net Income	-$191.09M	$23.81M	$3.57B	$336.71M
7 Day Performance	2.98%	5.65%	3.62%	2.55%
1 Month Performance	24.56%	8.27%	4.40%	0.32%
1 Year Performance	298.30%	64.81%	35.81%	25.76%

Sutro Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STRO Sutro Biopharma	3.1538 of 5 stars	$30.43 +0.6%	$52.44 +72.3%	+344.7%	$501.09M	$102.48M	N/A	240	Gap Down
CMPS Compass Pathways	2.8774 of 5 stars	$15.07 +1.7%	$23.10 +53.3%	+320.6%	$2.00B	N/A	N/A	120	News Coverage
STOK Stoke Therapeutics	1.9433 of 5 stars	$32.39 +1.2%	$41.83 +29.2%	+180.8%	$1.99B	$184.42M	N/A	100	Positive News
AMLX Amylyx Pharmaceuticals	3.5438 of 5 stars	$18.70 +5.1%	$24.25 +29.7%	+180.0%	$1.98B	$87.37M	N/A	200
NUVB Nuvation Bio	4.2686 of 5 stars	$5.60 -1.0%	$12.50 +123.4%	+178.8%	$1.97B	$143.05M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STRO) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sutro Biopharma (STRO) Competitors

STRO vs. CMPS, STOK, AMLX, NUVB, and ATAI

How does Sutro Biopharma compare to Compass Pathways?

Summary

How does Sutro Biopharma compare to Stoke Therapeutics?

Summary

How does Sutro Biopharma compare to Amylyx Pharmaceuticals?

Summary

How does Sutro Biopharma compare to Nuvation Bio?

Summary

How does Sutro Biopharma compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sutro Biopharma (STRO) Competitors

STRO vs. CMPS, STOK, AMLX, NUVB, and ATAI

How does Sutro Biopharma compare to Compass Pathways?

Do insiders and institutionals believe in CMPS or STRO?

Do analysts rate CMPS or STRO?

Which has more volatility and risk, CMPS or STRO?

Which has preferable earnings & valuation, CMPS or STRO?

Does the media prefer CMPS or STRO?

Is CMPS or STRO more profitable?

Summary

How does Sutro Biopharma compare to Stoke Therapeutics?

Do institutionals and insiders hold more shares of STOK or STRO?

Do analysts rate STOK or STRO?

Does the media refer more to STOK or STRO?

Which has more volatility and risk, STOK or STRO?

Is STOK or STRO more profitable?

Which has stronger valuation & earnings, STOK or STRO?

Summary

How does Sutro Biopharma compare to Amylyx Pharmaceuticals?

Do insiders & institutionals have more ownership in STRO or AMLX?

Which has more volatility and risk, STRO or AMLX?

Does the media favor STRO or AMLX?

Do analysts prefer STRO or AMLX?

Is STRO or AMLX more profitable?

Which has higher earnings and valuation, STRO or AMLX?

Summary

How does Sutro Biopharma compare to Nuvation Bio?

Does the media favor STRO or NUVB?

Which has preferable earnings & valuation, STRO or NUVB?

Which has more volatility and risk, STRO or NUVB?

Do insiders and institutionals believe in STRO or NUVB?

Do analysts recommend STRO or NUVB?

Is STRO or NUVB more profitable?

Summary

How does Sutro Biopharma compare to Atai Beckley?

Which has higher earnings & valuation, ATAI or STRO?

Does the media prefer ATAI or STRO?

Do institutionals & insiders have more ownership in ATAI or STRO?

Which has more risk and volatility, ATAI or STRO?

Do analysts prefer ATAI or STRO?

Is ATAI or STRO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools